Available outside the United States only
Benefits of biomarkers in the detection and monitoring of NMIBC
Urinary biomarker tests can detect bladder cancer and its recurrence. As such they will play an important role in the future management of bladder cancer diagnosis and surveillance.
Due to the high frequency of recurrence, NMIBC surveillance is crucial. Current developments in medical diagnostics aim to significantly reduce the number and frequency of invasive procedures for surveillance, alleviating the heavy burden for the patient.
In the EAU NMIBC guidelines update of 2023, new data have been included in Chapter 5.7.3 and 8 on surveillance of NMIBC. Four promising urine biomarkers are added in the surveillance strategy of an individual patient.
Therefore, our expert editorial board has updated the comprehensive slide resource ‘Biomarkers for NMIBC’ with the new EAU guideline data as well as recent publications.
Take advantage of the work of our editorial board and download the comprehensive slide resource.
It’s a great resource to discuss with your peers and to train your residents!
View or download also our summary brochure on using biomarkers in NMIBC.
Available outside the United States only
Benefits of biomarkers in the detection
and monitoring of NMIBC
Urinary biomarker tests can detect bladder cancer and its recurrence. As such they will play an important role in the future management of bladder cancer diagnosis and surveillance.
Due to the high frequency of recurrence, NMIBC surveillance is crucial. Current developments in medical diagnostics aim to significantly reduce the number and frequency of invasive procedures for surveillance, alleviating the heavy burden for the patient.
In the EAU NMIBC guidelines update of 2022, new data have been included in Chapter 5.7.3 and 8 on surveillance of NMIBC. Four promising urine biomarkers are added in the surveillance strategy of an individual patient.
Therefore, our expert editorial board has updated the comprehensive slide resource ‘Biomarkers for NMIBC’ with the new EAU guideline data as well as recent publications.
Take advantage of the work of our editorial board and download the comprehensive slide resource.
It’s a great resource to discuss with your peers and to train your residents!
View or download also our summary brochure on using biomarkers in NMIBC.
Available outside the United States only
Benefits of biomarkers in the detection
and monitoring of NMIBC
Urinary biomarker tests can detect bladder cancer and its recurrence. As such they will play an important role in the future management of bladder cancer diagnosis and surveillance.
Due to the high frequency of recurrence, NMIBC surveillance is crucial. Current developments in medical diagnostics aim to significantly reduce the number and frequency of invasive procedures for surveillance, alleviating the heavy burden for the patient.
In the EAU NMIBC guidelines update of 2022, new data have been included in Chapter 5.7.3 and 8 on surveillance of NMIBC. Four promising urine biomarkers are added in the surveillance strategy of an individual patient.
Therefore, our expert editorial board has updated the comprehensive slide resource ‘Biomarkers for NMIBC’ with the new EAU guideline data as well as recent publications.
Take advantage of the work of our editorial board and download the comprehensive slide resource.
It’s a great resource to discuss with your peers and to train your residents!
View or download also our summary brochure on using biomarkers in NMIBC.
Use the Bladder EpiCheck® test in your clinical practice >>
Recommendations
Prof. Fred Witjes, Radboud UMC
Nijmegen, the Netherlands
Rob de Vos
Living with high grade NMIBC
Gerard Lensvelt
The burden of Living with bladder cancer
Keep your NMIBC patients safe during COVID-19, with Bladder EpiCheck
Editorial board
Hospital Motol and 2nd Faculty of Medicine, Charles University
Prague, Czech Republic
Conflict of interest
[20 October 2021]
Advisory board member Ferring; Oncofid – Fidia
Presenter for Astellas, Ipsen, Janssen
Editorial board member of BCaMonitor.org
Biography
Paolo Gontero
San Giovanni Battista (Molinette) Hospital – University of Turin School of Medicine
Turin, Italy
Conflict of interest
[7 July 2020]
Advisory Board, Recipient of Research Grants, Trial Investigator or Lecturer for Ipsen, Astellas, Ferring, Arquer Diagnostics, Cepheid, Medacs and Janssen;
Editorial board member of BCaMonitor.org.
Biography
Jørgen Bjerggaard Jensen
Aarhus University Hospital
Aarhus, Denmark
Conflict of interest
[26 May 2020]
Proctor for Intuitive Surgery;
Member of Advisory Boards at Ferring and Cepheid;
Speaker for Medac and Olympus;
Research collaboration with Photocure ASA, Medac, Roche, Ferring, Karl Storz, Olympus, Intuitive Surgery, Astellas, AstraZeneca, Cepheid, and EpiCheck;
Patent holder of the JB-One en bloc retriever;
Editorial board member of BCaMonitor.org.
Biography
Hugh Mostafid
Guildford, UK
Conflict of interest
[26 May 2020]
Cepheid Advisory Board;
Editorial board member of BCaMonitor.org.
Biography
Joost Boormans
Erasmus MC Cancer Institute
Rotterdam, the Netherlands
Conflict of interest
[08 February 2024]
Consultancy/speaker’s fee (all paid to Erasmus MC): Janssen, BMS, AstraZeneca, Merck AG/Pfizer, MSD, Bayer;
Research collaboration: Merck AG/Pfizer, MSD, Janssen, VitroScan;
Book writing: Astellas;
Editorial board member of BCaMonitor.org.
Biography
Morgan Rouprêt
Pitié-Salpêtrière Hospital –
AP-HP Sorbonne University
Paris, France
Conflict of interest
[29 June 2020]
Consultant/Advisory Board for Nucleix, Astellas, Ipsen, Janssen, Intuitive, AstraZeneca, Ferring, Arquer Diagnostics, Roche, MSD;
Editorial board member of BCaMonitor.org.